Elevated risk for gastric adenocarcinoma can be predicted from histomorphology.
The number of patients with gastric cancer has more than doubled since 1985 in developing countries. Thus, the questions of whether it can be predicted from gastritis morphology, who is at risk and who has a lower risk of developing gastric carcinoma are raised. H pylori-infection leads to erosions, ulcerations, carcinoma, mucosa associated lymphoid tissue (MALT)-lymphoma and extragastric diseases only in some individuals. The frequency of ulcerations among H pylori-infected individuals is estimated to be 13%, gastric cancer about 1% and MALT lymphoma around 0.1%. In the literature a multistep model from chronic active H pylori-infection through multifocal atrophy, intestinal metaplasia, dysplasia (intraepithelial neoplasia) and carcinoma has been described. But this model cannot be applied to all routine cases. Since risk factors such as metaplasia and atrophy are paracancerous rather than precancerous conditions, this raises the question whether there is a better morphological marker. Differences in topography, grade and activity of Helicobacter gastritis in the antrum and corpus might be good markers for identifying those who are at risk of developing gastric cancer. It is known that the so-called corpus dominant H pylori gastritis is found more frequently among individuals with early and advanced gastric cancer and within high risk populations. This is valid both for first-degree relatives of gastric cancer patients and for patients with gastric adenoma and hyperplastic polyps. In conclusion, corpus-dominant H pylori gastritis is significantly more common in patients with advanced and early gastric cancer, first-degree relatives of patients with gastric cancer, patients with gastric adenoma and gastric hyperplastic polyps. Therefore, all these patients are at risk of developing gastric cancer. Next, the question of who is at risk of developing corpus-dominant gastritis is raised. It appears that patients with a low acid output more frequently develop gastric cancer. Eradication therapy is never performed too early but probably sometimes too late after the patients pass a "point of no return". Large prospective long term studies are necessary to prove this and identify new reliable markers for gastric cancer development.
Vieth
Michael
M
Institute of Pathology, Klinikum Bayreuth, Preuschwitzer Str. 101, 95445 Bayreuth, Germany.
Stolte
Mandred
M
D000230:Adenocarcinoma / Q000453:epidemiology / Q000209:etiology* / Q000382:microbiology; D004381:Duodenal Ulcer / Q000473:pathology; D005756:Gastritis / Q000473:pathology*; D016481:Helicobacter Infections / Q000150:complications / Q000473:pathology; D016480:Helicobacter pylori; D006801:Humans; D011127:Polyps / Q000473:pathology; D012307:Risk Factors; D013270:Stomach / Q000473:pathology*; D013274:Stomach Neoplasms / Q000453:epidemiology / Q000209:etiology* / Q000382:microbiology